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Abstract 
I use data on cumulative tests, positive tests, and deaths for the coronavirus in South Korea and the 
U.S. lower-48 states during April 2020 to estimate the extent of infection and the unidentified share 
of the infected population in each state and in the U.S. as a whole on April 21, 2020.  I find that 3.8 
million people, or 1.2% of the population, have been infected in the U.S., with rates of infection that 
range from 0.1% in more rural states to 7.0% in New York state.  I estimate that only 20% of all U.S. 
cases have been identified through testing.  The unidentified share of total cases ranges from 61% to 
83% across the states.  I estimate that 38% of all cases are asymptomatic, which is consistent with the 
high shares of unidentified cases.      
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Extremely limited testing for the coronavirus until recently and the uncertain share of 
asymptomatic cases has led to considerable speculation about the extent of coronavirus infection in 
the U.S. population.  Confirmed tests indicate that hundreds of thousands have been infected, but 
some researchers have argued that a huge share of the population is already infected, citing 
preliminary results from antibody testing [Silverman, Hupert, and Washburn, 2020].   
Researchers have been waiting for antibody tests to provide definitive data on the extent of 
the infection, but sufficient valid tests for mass testing may not be available for some time.   
Researchers have warned recently that many of the tests now coming to market are not reliable 
[Eder, Twohey, and Mandavilli, 2020].  These tests may be unable to distinguish between COVID-
19 and other coronaviruses associated with less serious respiratory illnesses [Cohen, 2020].   
In the absence of reliable results from antibody testing, in this paper I use state level data on 
positive coronavirus test rates and associated death rates, combined with an estimate of the death 
rate from the virus in South Korea, to estimate the number of coronavirus cases in each state and in 
the overall U.S. on April 21, 2020.  This analysis is based on the assumption that, unlike the situation 
in other countries, South Korea’s documented experience with the coronavirus is accurate and 
complete, so its death rate provides a benchmark for determining the true levels of coronavirus 
infection in the U.S. 
The hypothesis behind the estimation methodology for the U.S. is that first, the share of 
positive tests in a state is a valid indicator of the share of the infected population that has been 
identified through testing.  Second, the lower the share of positive tests, the higher the share of the 
infected population that has been identified.  Third, the relationship between the shares of positive 
tests and the actual number of infected people in each state can be determined using the death rate 
estimated in South Korea and the relationship between the positive test rates and death rates in the 
48 U.S. states.     
The results from the analysis show a logarithmic relationship between the death rate and the 
positive share of tests across states.  Applying this relationship to the data reveals that the rates of 
infection in the U.S. are highly skewed, with New York experiencing a 7% rate of infection, while 
Wyoming and a number of other more rural states have an infection rate of only 0.1%.  Overall the 
analysis here indicates that the coronavirus has infected 3.8 million people, or 1.2% of the U.S. 
population, a large number, but nowhere near enough to create herd immunity.     
The analysis also shows that only 20% of the infected individuals in the U.S. have been 
identified through testing through April 21, 2020.  The other 80%, numbering over three million 
people, are too numerous to identify through contact tracing.  South Korea managed to control the 
spread of the virus through a contact tracing process, but they only had 10,600 total cases.   
 The remainder of this paper is organized as follows:  Section II presents the methodology 
used to create the estimates of the infected population.  Section III presents the estimate of the 
death rate (deaths/total infections) associated with COVID-19 in South Korea.  Section IV presents 
an estimate of the asymptomatic share of coronavirus cases.  Section V presents the U.S. state data 
on the share of positive tests and the estimated death rates and the model to estimate the infected 
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share of the population in each state.  Section VI presents the state-by-state and national estimates 
of the share of the U.S. population infected with the virus and the share of unidentified cases on 
April 21, 2020.  Section VII concludes.      
II. Methodology 
No states in the U.S. have managed to test enough people to determine the share that has 
the disease.  The availability of tests has been so limited that no states have even managed to test all 
of the individuals with symptoms indicating that they might have the disease.  No states have 
attempted to identify the asymptomatic cases. 
In the approach taken here I estimate the infected share of the population in each state using 
the estimated death rates for the lower-48 states.  If there is a known expected rate of death from 
the disease, then the death rates for those confirmed to have the disease can be used to estimate the 
missing share of infected individuals in the population.  For example, if the true death rate 
(deaths/infected population) is known to be equal to 2% and the death rate among those tested is 
4%, then the population tested is a sample containing only half of the infected individuals. 
I do not use the death rate in each state to estimate the total cases in the state, because these 
rates vary based on the particular population (e.g., nursing homes) that happened to become 
infected in a state.  Instead I use the death rates in all of the states to estimate a relationship between 
the share of positive tests in a state and the death rate.  I do this because the share of positive tests 
relates more closely to the share of the total cases that have been identified in the state than its 
particular death rate.   
I first use the South Korean data to estimate the death rate for coronavirus in a population 
where everyone with the virus appears to have been tested.  I use the estimated average lag between 
the onset of the disease and death from the UK and China and estimates of the lag between testing 
and reporting in South Korea to calculate the deaths in South Korea that correspond to the reported 
cases.  I use this same approach to estimate the death rates in the U.S. by state.  After comparing the 
distribution of cases by age in South Korea and the U.S., I conclude that they are sufficiently similar 
to use the South Korean death rate as a reasonable estimate of the actual death rate in the U.S.  
I then plot the death rate in each state vs. the share of positive tests on April 7th and use a 
logarithmic trendline to determine the relationship between these two variables in the state data.  
The logarithmic relationship provides the best fit to the data.   
I then calculate the ratio between the estimated death rate and the South Korean death rate 
to determine the relationship between the total cases and the reported cases in each state.  This 
relationship provides the basis to estimate the identified and unidentified shares of the total cases in 
each state.  It also provides the basis to estimate the number of infected individuals in each state, 
which in total provides a national estimate of the infected population in the U.S.   
The Daily Mail has published a time line to show the progression of the disease in the UK 
[Boyd, 2020].  This time line is shown in Figure 1.  It shows five days from contagion to the onset of 
symptoms and 18-21 days from the onset of symptoms until death.  This estimate is similar to that 
of Verity et al. [2020], who used data for 24 patients in China to estimate that the average delay from 
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I assume that the lag between the onset of symptoms and death is 19 days in both South 
Korea and the U.S.  I use information about the test reporting lags in South Korea and the U.S. 
during April to estimate the death rates associated with the reported cases of the virus in each 
country.     
I validate the methodology by examining whether the estimates of the unidentified share of 
cases in each state are consistent with its reported testing strategy and the limitations on the 
availability of testing in March and early April.  In addition, since the states did not test 
asymptomatic individuals, I also examine whether the estimated shares of unidentified cases are 
consistent with my estimate from existing studies of the share of all cases that have been found to be 
asymptomatic.  I examine three studies and end up using the data from a screening study in Iceland 
and a study of the distribution of case severity in China to determine the asymptomatic share.   
III. The Death Rate in South Korea 
The death rate is the share of positive cases that end in death.  Since countries generally only 
count a fraction of the symptomatic cases, the number of deaths divided by the number of reported 
cases on the same date substantially overestimates the true death rate.  In addition, deaths occur later 
than reported cases, so when cases are rising, the death rate calculated from cases and deaths on the 
same date is underestimated.  Death rates may also be underestimated if individuals die of 
coronavirus without any testing for the disease and their cause of death is attributed to something 
else, such as pneumonia.  
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Clearly the best estimate of the death rate from all cases of coronavirus would come from a 
large representative sample of the population used to determine the share infected and a follow-up 
study of the infected group to identify the share of this group that died.  No country has carried out 
such a study, although Iceland has done part of such a study.     
South Korea has pursued an alternative approach, in which they attempted to identify all the 
cases of infection in the country, including those with no symptoms, and then tracked these 
individuals to determine the associated deaths.  The government mobilized the entire population to 
identify all cases of the coronavirus and carried out the highest rate of testing per capita in the world.  
It set up drive-by testing, so anyone with symptoms or suspected of being infected could quickly be 
tested.  It then followed up every positive test with thorough contact tracing and tested the contacts, 
whether they had symptoms or not [DW, 2020].   
The evidence indicates that the government managed to find and test almost every 
symptomatic and asymptomatic case in the country.  Since the number of new cases declined to 
almost zero in April, there must not have been many asymptomatic individuals who were not tested, 
identified, and quarantined.  This means that South Korea is unique among countries in including all 
of its asymptomatic cases in the national estimate of total cases.   
The delay between the onset of symptoms and a confirmed test result is short in South 
Korea due to the prevalence of testing facilities and its high testing capacity relative to the number 
of individuals suspected of being infected.  The Government of the Republic of Korea [2020] 
estimated that in early April this delay was 2-3 days.  I assume 19 days between the onset of 
symptoms and death, which leaves 16 days as the average lag between confirmed test results and 
death at that time.   
As shown in Table 1, the cumulative confirmed cases of the virus in South Korea on April 
4th was 10,156 and the deaths sixteen days later on April 20th were 236.  This yields a death rate for 
all cases of the virus of 2.3%.   
 
 Table 1 













April 4th  10,156      
April 18th 541,284 10,653 232 51,600,000 2.0%  0.02% 
April 20th 551,0541 10,674 236 51,600,000 2.0% 2.3% 0.02% 
Source: Roser, Ritchie, Ortiz-Ospina and Hasell (2020) 
111,981 tests outstanding (2-3 days) 
 
This rate could be low if some deaths are yet to occur or are not included in the statistics, 
but this is unlikely due to the small number of recent coronavirus cases and the government’s 
coronavirus reporting practices.  The data in the table show that in the two days prior to April 20th 
there were only 21 new cases and two new deaths.  These numbers are so small that slight increases 
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would have no noticeable effect on the ratio of cumulative deaths/cumulative cases in mid-April.  In 
addition, deaths are unlikely to be underestimated because South Korea attributes all deaths of 
persons who tested positive for the coronavirus to the virus, even if they had other underlying 
health conditions [AFP-JiJi, 2020]. 
The average death rate is very sensitive to the age distribution of infected individuals in a 
country because death rates are much higher for older patients.  So the South Korean death rate is 
only applicable for the U.S. if the age distributions of coronavirus patients are similar in both 
countries.   
Table 2 compares the age distribution of reported Coronavirus cases in South Korea and the 
U.S. in April, 2020.  Since the available data for the two countries were reported for slightly different 
age categories, I created a distribution for the U.S. by decades for comparability with the decadal 
data available for South Korea.  A comparison of the two distributions shows that the share of cases 
in the U.S. distribution is more heavily weighted toward the older age categories, with 40% of the 
cases in the over-60 group compared to only 25% for this group in South Korea.  
 Due to the testing limitations, the U.S. data on positive tests in April exclude a considerable 
share of the mild and moderate cases and all of the asymptomatic cases.  Since these cases are more 
frequent in the young than in the old, their exclusion in the U.S. reduces the share of reported cases 
in the younger age categories.  If the missing mild and moderate cases in the U.S. were added to the 
total cases, the U.S. distribution would become more like the South Korean distribution.  Lacking 
data on a large share of coronavirus cases in the U.S., I assume for the analysis that the age 
distributions are similar in the two countries and that the South Korean death rate of 2.3% is 
applicable for the actual death rate in the U.S. when all cases of the coronavirus are included.     
Table 2 
Age Distribution of Cases in South Korea and the U.S.  
(Percent) 
Age Categories South Korea* U.S.** 
0-9 1 1 
10-19 5 4 
20-29 27 11 
30-39 11 11 
40-49 13 15 
50-59 18 18 
60-69 13 17 
70-79 7 13 
80+ 5 10 
*Statista, 2020 for April 16th 
**Sonnemaker and Kiersz, 2020 
 
IV. The Asymptomatic Share of Total Cases 
My methodology does not require an explicit estimate of the asymptomatic share of all 
coronavirus cases.  But an estimate for this portion of the cases is useful because it provides a 
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minimum estimate of the missing share of cases in the U.S.  Few states have made any effort to 
perform contact tracing, so reported coronavirus cases in the U.S. rarely include asymptomatic cases.   
Few countries manage to identify the asymptomatic cases.  South Korea has included these 
cases in their estimates, but it has not provided data on the asymptomatic share, perhaps because 
this would require that investigators monitor asymptomatic cases to determine whether they become 
symptomatic later.      
Iceland has carried out the only large screening study designed to determine the 
asymptomatic share of coronavirus cases in the population [Gudbjartsson, et al., 2020].  Two groups 
were tested that included 13,080 participants in total, of which one was self-selected and the other 
was picked at random.  Only 17% of the participants were selected at random, but the share testing 
positive in this group was similar to the share in the entire sample.  Out of the total participants in 
both groups, 100 individuals (0.6%) tested positive and were quarantined for 14 days, and 43% 
reported that they were asymptomatic during this period.  If any of these individuals developed 
symptoms later, the asymptotic share would be lower, but this seems relatively unlikely after a 14-day 
quarantine.   
The study excluded individuals with severe symptoms, such as those that would be 
hospitalized, so the 43% asymptotic share in the study is an overestimate of the actual share in the 
population.  A WHO-China joint mission analyzed Chinese data for a large group of coronavirus 
patients and determined that about 20% of all symptomatic cases required hospitalization [Verity, 
2020].  Assuming this ratio is applicable to Iceland, adding the severe cases raises the 57 
symptomatic cases in the study to 71, which reduces the asymptomatic share to 38% (43/71+43).  
This seems to be the best currently available estimate of the asymptotic share of coronavirus cases.     
In another study Nishiura et al. [2020] evaluated the asymptomatic share of cases in the 565 
Japanese citizens evacuated from Wuhan and placed in quarantine for 14 days.  Thirteen tested 
positive for coronavirus, of which nine had symptoms or developed them during the quarantine and 
four did not.  The asymptomatic share of coronavirus patients is 31%, but the sample is too small to 
be very precise.     
Mizumoto, et al.[2020] estimated the asymptomatic share of those passengers on the 
Diamond Princess cruise ship who tested positive.  Since the initial testing for coronavirus was not 
random and the asymptomatic passengers could not be monitored after they left the ship, their 
estimate is heavily based on modeling assumptions.  They estimate that the asymptomatic share of 
53% at the time they left the ship probably declined to 18% later.    
The estimate from the Icelandic study that 38% of all coronavirus cases are asymptotic is the 
most robust of the three estimates.  Given the greater uncertainty associated with the Nishiura et al. 
and Mizumoto et al. estimates, the 38% figure appears to be consistent with all three studies.   
V. U.S. Data on the Share of Positive Tests and the Associated Death Rates 
Several groups track the numbers of U.S. tests, confirmed cases, and deaths by state and 
publish their results several times a day.  These data can be used to calculate the share of individuals 
that test positive and the death rates associated with the confirmed cases.   
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As discussed earlier, the number of reported cases of the coronavirus are a subset of the 
actual number of cases because the U.S. did not have sufficient testing capacity to test all of the 
individuals with coronavirus symptoms.  The method of rationing the limited available tests was 
similar across states because the CDC issued guidelines for testing priorities [Connor, 2020]: 
• Priority one: Hospitalized patients and symptomatic healthcare workers 
• Priority two: High-risk patients with coronavirus symptoms 
• Priority three: Symptomatic individuals in the community, if resources allow 
None of these priorities include asymptomatic individuals. 
The likelihood that tests would be positive was highest for individuals in Priority one and 
declines in Priority two and three.  As a result, as the number of tests increases, testing is extended 
to groups less and less likely to test positive, and the positive share of cumulative tests declines.  
States overwhelmed with coronavirus cases tested only a small fraction of all the individuals they 
thought were infected and obtained very high shares of positive tests.   
Figure 2 shows the share of cumulative positive tests by state for the lower-48 states and 
South Korea on April 7th, using U.S. data published in Politico [Jin, 2020].  These data show that 
about half the states have shares of positive tests under 10%, with the lowest share at 3%.  All of the 
states have a higher share of cumulative positive tests than South Korea (at 2%).  Five states have 
shares of cumulative positive tests over 20%, and three states have shares over 30%.  These three 
states, New Jersey, New York, and Michigan, are the ones who have reported tremendous 
limitations on their capacity to test individuals with coronavirus symptoms.   
Maag [2020] reports that in late March very sick New Jersey residents spent many nights in 
their cars waiting in line at testing stations after being turned away in emergency rooms.  In late 
March New York City restricted testing to hospitalized patients to prevent the many infected 
individuals with less serious symptoms from leaving home [Cuzey, 2020].  Michigan restricted 
testing to those with the most serious symptoms until testing was extended to those with mild 
symptoms in mid-April [Clarke, 2020]. 
At the beginning of April, Georgia, another state a with high shares of cumulative positive 
tests (18%), restricted tests to very sick patients, including those in group situations, such as nursing 
homes, and emergency and health care workers [Trubey, 2020].   Testing continued to be restricted 
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Until mid-March even states with lower shares of cumulative positive tests, such as 
California and Rhode Island, reported that they could not test everyone who needed a test [Becker, 
2020 and Mooney, 2020].  Even in mid-April 2020, after testing capacity in the U.S. improved 
relative to the number of suspected coronavirus cases, tests in most locations were still rationed to 
the higher priority applications [Connor, 2020].   
Patients with severe symptoms and elderly and vulnerable patients with less severe 
symptoms were tested, and some states tested a large share of individuals with mild or moderate 
symptoms, but there was no contact tracing system that might lead to testing of asymptomatic 
individuals.  Some patients died at home or in nursing homes without ever being tested.  As a 
consequence, the confirmed cases reported by the states do not include asymptomatic cases and do 
not include an unknown share of patients with mild, moderate, and even severe symptoms.   
Death rates (deaths/infected population) for coronavirus calculated from the confirmed 
cases for most states are much higher than the 2.3% rate in South Korea.  Although death rates for 
the virus vary as a function of the patient’s age and the quality and availability of medical care, there 
is no reason to believe that on average a higher share of Americans than South Koreans are likely to 
die from the virus.  This means that the higher average death rates in the U.S. are likely to be due 
largely to the missing cases of infected individuals in the data.   
If this is the case, then we should also expect to see a strong correlation between the share 
of cumulative positive tests and the death rates across states.  Death rates could vary due to many 
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factors, but a higher share of individuals testing positive is almost certain to indicate that the more 
difficult coronavirus cases to identify are missing from the data.     
Figure 3 shows a plot of the coronavirus death rate from cumulative reported cases and the 
share of cumulative positive tests for reported cases in the lower-48 states through April 7, 2020.  
The death rates are calculated using total cumulative deaths on April 21st divided by total cumulative 
positive cases on April 7th.   
As discussed earlier, the average lag between the onset of symptoms and death is estimated 
to be about 19 days.  Initially test results were only reported in the U.S. with very long lags, but in 
early April the lag became much shorter, as the public’s awareness of the virus became widespread 
and private laboratories began to perform large numbers of tests on a more expedited basis.  The 
reported lag for test results from LabCorp and Quest Diagnostics on April 8th was 3-4 days [Strickler 
and Kaplan, 2020].  With this lag for results, I assume that the average time lag between the onset of 
symptoms and test results on April 7th was 5 days.  This leaves a 14-day average lag between reports 
of cases of coronavirus and the deaths associated with these cases.        
I use Jin’s [2020] data on cumulative tests and positive test results by state on April 7th and 
the New York Times’ data on cumulative deaths by state on April 21st to calculate the share of 
positive tests and the death rates for the lower-48 states.  Both sources report the positive test 
results, but neither includes all three measures.  A comparison of their positive test results for the 
same days shows that the two data sets are similar, but not identical, which is not surprising given 
that the data are updated at different times over the course of each day.  
Figure 3 
Apparent U.S. Death Rates vs. Positive Shares of Tests on April 7th 
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The data for the death rate and the positive share of tests in the figure show a definite 
positive logarithmic relationship (R2 = 0.30).  As the positive share of cumulative tests rises across 
states for the period through April 7th, the calculated death rate rises, but at a decreasing rate.  The 
share of cumulative positive tests associated with the assumed 2.3% true death rate in the trendline 
is 1%, which is close to the 2% share of positive tests at that death rate in South Korea.  The 
estimated relationship of the death rate (deaths/infected population) to the share of cumulative 
positive tests is: 
1) Death rate = 0.0289 ln(share of positive tests) + 0.1554 
This relationship can be used to estimate the ratio of the actual infected population to the identified 
infected cases as a function of the positive share of cumulative tests in each state, assuming that 
there are no missing cases of infection when the death rate equals 2.3% (as in South Korea): 
2) TotaI Cases/Identified Cases = 1.257 ln(positive share of tests) + 6.757  
Equation (2) can be used to estimate the total number of coronavirus cases in each state.  The sum 
of all the cases can be used to estimate the infected share of the U.S. population.  These results are 
shown in the next section. 
Equation (2) is based on the assumption that the reported deaths due to the coronavirus in 
the U.S. are as complete and comparable to the reported deaths in South Korea.  This is almost 
certainly not the case because many deaths in the U.S. involved elderly patients who died at home or 
in nursing homes without ever being tested for the virus.  Until recently, these deaths were often 
attributed to pneumonia, to some underlying condition, or to some fatal physiological response to 
the virus, such as a stroke.   
As discussed earlier, South Korea attributed any deaths of patients who tested positive to the 
coronavirus to the virus.  Medical providers in the U.S. could not and did not do this because they 
tested only a small fraction of the patients who had the disease.   
Coroners in many countries are now reviewing deaths that occurred over the last few 
months attributed to other causes to determine whether COVID-19 was the actual cause of death, 
and they are raising the number of deaths attributed to the virus.  As coroners in the U.S. raise their 
estimates of the deaths that were due to the coronavirus, states may or may not include these 
revisions in the statistics reported to the CDC.  Even if they do, these deaths show up later, so the 
cumulative deaths included in the New York Times data for a particular date may underestimate the 
total number of deaths [Wu, McCann, Katz, and Peltier, 2020].    
The deaths reported for New York by the New York Times include those associated with 
patients who tested positive for the coronavirus in New York City, but apparently do not include 
deaths that the City is now saying were probably caused by the virus.  There appear to be about 
5,000 of these probable deaths through April 21st [Bui, Katz, Parlapiano, and Sanger-Katz, 2020].   
Including these deaths to calculate the cumulative New York death rate raises the rate from 11.0% 
to 14.8%, which would slightly raise the slope of the trendline shown in Figure 3.  This change for 
this one state does not have much effect on the estimated relationship in Equations (1) and (2), as 
long as the rates in other states are not changed.    
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No statistics are available to estimate the magnitude of the missing deaths in the U.S. data 
for all the states, but some researchers are comparing the recent surge in mortality to the deaths 
attributed to the virus to see whether the underreporting of deaths due to the virus could be 
substantial.  The New York Times has estimated that the surge in mortality in New York City in 
recent months was 30% larger (17200/13240) than the reported deaths attributed to the coronavirus 
[Wu, McCann, Katz, and Peltier, 2020].  New York City’s recent addition of probable deaths from 
the coronavirus implicitly attributes all of the recent surge in mortality to the virus.   
Of course, even if these additional deaths in NYC are due to the virus, this does not imply 
that the magnitude of this increase is relevant for the death statistics reported throughout the U.S.  
What is clear is that the deaths reported by the states to estimate the U.S. death rates in the analysis 
are underestimated by some amount, which means that the ratio of total cases/identified cases in 
Equation (2) is underestimated.  Still, the estimates of total cases/identified cases produced by the 
Equation are sufficiently accurate to be indicative of the actual total cases in the country.              
Another way to evaluate whether Equation (2) is reasonable is to apply it to the states with 
the lowest and highest shares of positive tests to see if the estimated sizes of the unidentified share 
of the infected population seem reasonable, given the known testing conditions in those states.   
Applying equation (2) to North Dakota, one of the states with the lowest share of positive 
tests (3.1%) on April 7th, the equation indicates that the state identified 42% of the total cases of 
infection and failed to identify 58% of these cases.  Since 38% of the cases are estimated to be 
asymptomatic, if the state did not identify any of these cases, then it identified 68% of the 
symptomatic cases (42/62).  Given the extensive testing relative to the number of symptomatic cases 
in this state, this estimate seems reasonable.    
Applying equation (2) to New Jersey, the state with the highest share of positive tests 
(46.2%) on April 7th, the equation indicates that the state identified 17% of the total cases of 
infection and failed to identify 83% of these cases.  Since 38% of the cases are estimated to be 
asymptomatic, if the state did not identify any of these cases, then it identified 27% of the 
symptomatic cases (17/62).  Given that about 20% of all symptomatic cases require hospitalization, 
if the state identified all of these cases, then the implication is that it only managed to identify 8% of 
the existing cases with mild or moderate symptoms.  Given the reports on the tremendous difficulty 
encountered by individuals seeking tests in New Jersey in late March, this estimate also seems 
reasonable.      
The data used to estimate Equation (1) are included in the Appendix.   
VI. Estimated Total and Unidentified Coronavirus Cases 
Table 2 presents the results for an application of the model using the data on April 21st for 
the share of positive test results in each state.  The state results are used to calculate results for the 
U.S. as a whole.  For each state the table shows the ratio of total cases/reported cases, the share of 
unidentified cases, and the infected share of the population.  
What is striking is that most cases in every state are unidentified.  Overall, only 20% of all 
cases have been confirmed through testing, and 80% have not been identified.  The unidentified 
share ranges from 61% to 83% across states.  The total number of unidentified cases in the U.S. was 
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about 3 million.  This finding demonstrates how difficult it would be to contact trace all the cases in 
the U.S. at the current stage of the epidemic.  
The rate of infection in the U.S. varies dramatically across states, from about 0.1% in 
Wyoming, Montana, West Virginia, Minnesota, and Oregon to 7.0% in New York.  Contact tracing 
would be feasible, at least in theory, in states with the lower rates of infection, as South Korea 
managed to do it with a 0.2% infected share of the population.   
Table 2 















Alabama 5,025 45,900 10.9% 3.98 19982 74.9% 4,858,979 0.4% 
Arizona 5,064 54,500 9.3% 3.77 19093 73.5% 6,828,065 0.3% 
Arkansas 1,923 26,553 7.2% 3.46 6648 71.1% 2,978,204 0.2% 
California 30,978 290,50
0 
10.7% 3.94 122159 74.6% 39,144,81
8 
0.3% 
Colorado 9,730 46,195 21.1% 4.80 46695 79.2% 5,456,574 0.9% 
Connecticut 19,815 62,806 31.5% 5.31 105156 81.2% 3,590,886 2.9% 
Delaware 2,745 16,470 16.7% 4.50 12366 77.8% 945,934 1.3% 
Florida 26,660 266,22
5 
10.0% 3.86 103025 74.1% 20,271,27
2 
0.5% 
Georgia 18,947 84,328 22.5% 4.88 92465 79.5% 10,214,86
0 
0.9% 
Idaho 1,672 17,445 9.6% 3.81 6369 73.7% 1,654,930 0.4% 
Illinois 31,508 148,35
8 
21.2% 4.81 151535 79.2% 12,859,99
5 
1.2% 
Indiana 11,686 64,639 18.1% 4.61 53837 78.3% 6,619,680 0.8% 
Iowa 3,159 25,820 12.2% 4.12 13003 75.7% 3,123,899 0.4% 
Kansas 1,986 18,761 10.6% 3.93 7813 74.6% 2,911,641 0.3% 
Kentucky 2,960 32,572 9.1% 3.74 11077 73.3% 4,425,092 0.3% 
Louisiana 24,523 142,09
9 
17.3% 4.55 111544 78.0% 4,670,724 2.4% 
Maine 875 14,951 5.9% 3.19 2791 68.6% 1,329,328 0.2% 





23.5% 4.94 187910 79.7% 6,794,422 2.8% 
Michigan 32,000 113,79
8 
28.1% 5.16 165192 80.6% 9,922,576 1.7% 
Minnesota 2,470 46,850 5.3% 3.06 7553 67.3% 5,489,594 0.1% 
Mississippi 4,512 51,434 8.8% 3.70 16685 73.0% 2,992,333 0.6% 
Missouri 5,807 56,013 10.4% 3.91 22694 74.4% 6,083,672 0.4% 
Montana 433 11,051 3.9% 2.68 1163 62.8% 1,032,949 0.1% 
Nebraska 1,474 15,680 9.4% 3.78 5579 73.6% 1,896,190 0.3% 





1,392 14,118 9.9% 3.84 5352 74.0% 1,330,608 0.4% 
New Jersey 88,806 178,05
7 
49.9% 5.88 522407 83.0% 8,958,013 5.8% 
New 
Mexico 

















627 14,747 4.3% 2.79 1748 64.1% 756,927 0.2% 
Ohio 12,516 90,436 13.8% 4.27 53457 76.6% 11,613,42
3 
0.5% 
Oklahoma 2,680 35,646 7.5% 3.50 9391 71.5% 3,911,338 0.2% 










5,090 37,080 13.7% 4.26 21688 76.5% 1,056,298 2.1% 
South 
Carolina 
4,377 40,480 10.8% 3.96 17337 74.8% 4,896,146 0.4% 
South 
Dakota 
1,685 12,326 13.7% 4.26 7171 76.5% 858,469 0.8% 
Tennessee 7,238 100,68
9 
7.2% 3.45 24955 71.0% 6,600,299 0.4% 
Texas 19,458 190,39
4 
10.2% 3.89 75691 74.3% 27,469,11
4 
0.3% 
Utah 3,213 68,311 4.7% 2.91 9364 65.7% 2,995,919 0.3% 
Vermont 816 12,981 6.3% 3.28 2676 69.5% 626,042 0.4% 
Virginia 8,990 56,735 15.8% 4.44 39927 77.5% 8,382,993 0.5% 
Washington 11,790 138,64
2 
8.5% 3.66 43139 72.7% 7,170,351 0.6% 
West 
Virginia 
902 22,155 4.1% 2.73 2465 63.4% 1,844,128 0.1% 
Wisconsin 4,499 51,102 8.8% 3.70 16658 73.0% 5,771,337 0.3% 











VII.  Conclusions 
The U.S. is testing to identify cases of the coronavirus, but the testing has been completely 
inadequate to determine the extent of infection in the population.  This study uses the death rate and 
the share of positive tests in each state to estimate the share of cases in each state that have been 
identified and the size of the infected population.  The results indicate that no state has managed to 
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identify even half of the cases, so it is difficult to control the spread.  But it is also clear that not all 
states have been severely affected by the virus, with rates of infection on April 21, 2020 ranging 
from 0.1% to 7.0% of the population.   
Overall 3.8 million people have been infected, which is 1.2 percent of the population.  This 
is nowhere near a high enough share to create herd immunity, but it is too many people to permit 
contact tracing for all of them in the states with the highest infection rates.  The wide differences in 
rates of infection indicate that different strategies are appropriate to manage the virus in different 
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Data Used to Estimate the Model on April 7, 2020 
 
Positive Tests Positive share Deaths Death Rate 
Alabama 1,968 14,765 13.3% 173 8.8% 
Arizona 2,456 32,534 7.5% 191 7.8% 
Arkansas 875 12,845 6.8% 42 4.8% 
California 14,336 117,431 12.2% 1225 8.5% 
Colorado 4,950 25,773 19.2% 448 9.1% 
Connecticut 6,906 26,686 25.9% 1331 19.3% 
Delaware 673 6,994 9.6% 72 10.7% 
Florida 13,324 123,274 10.8% 822 6.2% 
Georgia 7,314 40,012 18.3% 767 10.5% 
Idaho 1,101 10,995 10.0% 48 4.4% 
Illinois 12,262 62,942 19.5% 1359 11.1% 
Indiana 4,944 26,191 18.9% 569 11.5% 
Iowa 946 11,599 8.2% 79 8.4% 
Kansas 845 9,084 9.3% 101 12.0% 
Kentucky 955 18,767 5.1% 155 16.2% 
Louisiana 14,867 69,166 21.5% 1328 8.9% 
Maine 499 6,587 7.6% 35 7.0% 
Maryland 4,045 29,617 13.7% 516 12.8% 
Massachusetts 13,837 76,429 18.1% 1809 13.1% 
Michigan 17,221 47,251 36.4% 2466 14.3% 
Minnesota 986 28,128 3.5% 143 14.5% 
Mississippi 1,738 20,370 8.5% 169 9.7% 
Missouri 2,722 29,835 9.1% 211 7.8% 
Montana 299 6,790 4.4% 12 4.0% 
Nebraska 409 6,787 6.0% 34 8.3% 
Nevada 1,953 17,629 11.1% 163 8.3% 
New Hampshire 669 8,370 8.0% 42 6.3% 
New Jersey 41,090 89,032 46.2% 4377 10.7% 
New Mexico 624 19,136 3.3% 58 9.3% 
New York 130,689 320,811 40.7% 14347 11.0% 
North Carolina 2,870 40,726 7.0% 187 6.5% 
North Dakota 225 7,213 3.1% 13 5.8% 
Ohio 4,450 48,378 9.2% 509 11.4% 
Oklahoma 1,327 16,588 8.0% 143 10.8% 
Oregon 1,068 20,624 5.2% 75 7.0% 
Pennsylvania 12,980 83,854 15.5% 1366 10.5% 
Rhode Island 1,082 8,481 12.8% 155 14.3% 
South Carolina 2,049 18,976 10.8% 124 6.1% 
South Dakota 288 6,020 4.8% 7 2.4% 
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Tennessee 3,802 47,350 8.0% 162 4.3% 
Texas 7,276 85,357 8.5% 523 7.2% 
Utah 1,675 33,394 5.0% 28 1.7% 
Vermont 543 6,633 8.2% 38 7.0% 
Virginia 2,878 24,521 11.7% 300 10.4% 
Washington 7,984 91,375 8.7% 661 8.3% 
West Virginia 345 9,940 3.5% 26 7.5% 
Wisconsin 2,440 29,014 8.4% 231 9.5% 
Wyoming 210 3,929 5.3% 2 1.0% 
Total 358,995 1,898,203 18.9% 37,642 10.5% 
 
 
